

Resource Summary Report

Generated by [NIF](#) on Sep 10, 2026

ML-2

RRID:CVCL_1418

Type: Cell Line

Proper Citation

RRID:CVCL_1418

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1418

Proper Citation: RRID:CVCL_1418

Description: Cell line ML-2 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Adult acute myeloid leukemia

Defining Citation: [PMID:2985879](#), [PMID:3159941](#), [PMID:3458526](#), [PMID:3874327](#), [PMID:6091813](#), [PMID:14671638](#), [PMID:15843827](#), [PMID:16408098](#), [PMID:16969076](#), [PMID:20164919](#), [PMID:20215515](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:30894373](#), [PMID:35839778](#)

Comments: Population: Caucasian., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: ML-2

Synonyms: ML2

Cross References: BTO:BTO_0001885, CLO:CLO_0007736, EFO:EFO_0002238, CLDB:cl3490, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-3610, BioSample:SAMN03472168, cancercellines:CVCL_1418, Cell_Model_Passport:SIDM00441, ChEMBL-Cells:ChEMBL3307604, ChEMBL-Targets:ChEMBL614356, Cosmic:787454, Cosmic:850389, Cosmic:908141, Cosmic:975271, Cosmic:999728, Cosmic:1012092, Cosmic:1078727, Cosmic:1078739, Cosmic:1151785, Cosmic:1181602, Cosmic:1281329,

Cosmic:1524834, Cosmic:2131545, Cosmic:2391904, Cosmic:2750863, Cosmic-CLP:908141, DepMap:ACH-002273, DSMZ:ACC-15, DSMZCellDive:ACC-15, EGA:EGAS00001000610, EGA:EGAS00001000978, EGA:EGAS00001002554, GDSC:908141, GEO:GSM236791, GEO:GSM236827, GEO:GSM482497, GEO:GSM1374683, GEO:GSM1446737, GEO:GSM1670116, IGRhCellID:ML2, LINCS_LDP:LCL-1060, PharmacDB:ML2_942_2019, PRIDE:PXD030304, Progenetix:CVCL_1418, PubChem_Cell_line:CVCL_1418, Wikidata:Q54905843

ID: CVCL_1418

Record Creation Time: 20220427T220810+0000

Record Last Update: 20260905T181150+0000

Ratings and Alerts

No rating or validation information has been found for ML-2.

No alerts have been found for ML-2.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 17 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Barral L, et al. (2026) Targeting BMP and TAZ/TEAD mechanotransduction pathways impairs acute myeloid leukemia chemoresistance. *Leukemia*, 40(6), 1151.

Jones L, et al. (2026) A structure-based modeling approach identifies effective drug combinations for RAS-mutant acute myeloid leukemia. *iScience*, 29(8), 116875.

Chen Z, et al. (2025) YTHDF2 promotes ATP synthesis and immune evasion in B cell malignancies. *Cell*, 188(2), 331.

Han L, et al. (2023) METTL16 drives leukemogenesis and leukemia stem cell self-renewal by reprogramming BCAA metabolism. *Cell stem cell*, 30(1), 52.

Ng M, et al. (2023) Myeloid leukemia vulnerabilities embedded in long noncoding RNA locus MYNRL15. *iScience*, 26(10), 107844.

Maru B, et al. (2023) PARP-1 improves leukemia outcomes by inducing parthanatos during chemotherapy. *Cell reports. Medicine*, 4(9), 101191.

Polyanskaya SA, et al. (2022) SCP4-STK35/PDIK1L complex is a dual phospho-catalytic signaling dependency in acute myeloid leukemia. *Cell reports*, 38(2), 110233.

Jayavelu AK, et al. (2022) The proteogenomic subtypes of acute myeloid leukemia. *Cancer cell*, 40(3), 301.

Hernández-Malmierca P, et al. (2022) Antigen presentation safeguards the integrity of the hematopoietic stem cell pool. *Cell stem cell*, 29(5), 760.

Cao Z, et al. (2021) ZMYND8-regulated IRF8 transcription axis is an acute myeloid leukemia dependency. *Molecular cell*, 81(17), 3604.

Miyamoto R, et al. (2021) HOXA9 promotes MYC-mediated leukemogenesis by maintaining gene expression for multiple anti-apoptotic pathways. *eLife*, 10.

Chen CC, et al. (2020) Vitamin B6 Addiction in Acute Myeloid Leukemia. *Cancer cell*, 37(1), 71.

Su R, et al. (2020) Targeting FTO Suppresses Cancer Stem Cell Maintenance and Immune Evasion. *Cancer cell*, 38(1), 79.

Krivtsov AV, et al. (2019) A Menin-MLL Inhibitor Induces Specific Chromatin Changes and Eradicates Disease in Models of MLL-Rearranged Leukemia. *Cancer cell*, 36(6), 660.

Volk A, et al. (2018) A CHAF1B-Dependent Molecular Switch in Hematopoiesis and Leukemia Pathogenesis. *Cancer cell*, 34(5), 707.

Reyna DE, et al. (2017) Direct Activation of BAX by BTSA1 Overcomes Apoptosis Resistance in Acute Myeloid Leukemia. *Cancer cell*, 32(4), 490.

Liang K, et al. (2017) Therapeutic Targeting of MLL Degradation Pathways in MLL-Rearranged Leukemia. *Cell*, 168(1-2), 59.